Sensus Healthcare, Inc. (NASDAQ:SRTS) Director John Heinrich Sells 4,773 Shares

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director John Heinrich sold 4,773 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $5.95, for a total transaction of $28,399.35. Following the sale, the director now directly owns 75,167 shares in the company, valued at $447,243.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

John Heinrich also recently made the following trade(s):

• On Monday, May 20th, John Heinrich sold 15,227 shares of Sensus Healthcare stock. The stock was sold at an average price of $6.24, for a total value of $95,016.48.

Sensus Healthcare Trading Up 3.0 %

Shares of SRTS traded up $0.18 during mid-day trading on Friday, hitting $6.10. 305,337 shares of the company traded hands, compared to its average volume of 1,389,191. The business has a 50-day moving average of $4.07 and a 200 day moving average of $3.40. Sensus Healthcare, Inc. has a one year low of $1.79 and a one year high of $6.55. The stock has a market capitalization of $99.98 million, a price-to-earnings ratio of 21.04 and a beta of 0.92.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.18. The firm had revenue of $10.66 million for the quarter, compared to analyst estimates of $4.33 million. Sensus Healthcare had a return on equity of 9.76% and a net margin of 14.70%. During the same period last year, the company earned ($0.12) EPS. As a group, analysts anticipate that Sensus Healthcare, Inc. will post 0.29 earnings per share for the current year.

Institutional Trading of Sensus Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SRTS. Sachetta LLC acquired a new position in Sensus Healthcare during the 4th quarter valued at about $247,000. Hillsdale Investment Management Inc. acquired a new position in Sensus Healthcare in the first quarter valued at approximately $155,000. Creekmur Asset Management LLC acquired a new position in Sensus Healthcare in the fourth quarter valued at approximately $83,000. Finally, Perritt Capital Management Inc. boosted its stake in Sensus Healthcare by 5.0% in the third quarter. Perritt Capital Management Inc. now owns 105,586 shares of the company’s stock valued at $292,000 after acquiring an additional 5,000 shares during the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. HC Wainwright raised their price target on Sensus Healthcare from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, May 13th. Maxim Group lifted their price target on Sensus Healthcare from $7.00 to $10.00 and gave the company a “buy” rating in a report on Friday, May 10th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.